Literature DB >> 6301152

2-5A synthetase activity does not increase in interferon-resistant Friend leukemia cell variants treated with alpha/beta interferon despite the presence of high-affinity interferon receptor sites.

E Affabris, G Romeo, F Belardelli, C Jemma, N Mechti, I Gresser, G B Rossi.   

Abstract

The presence of interferon (IFN) receptors on mouse Friend leukemia cells (FLC) has been investigated in binding experiments with highly purified 125I-labeled mouse alpha/beta IFN. Both IFN-resistant clones and wild-type IFN-sensitive FLC showed a specific saturable binding site for mouse IFN with a similar affinity constant. In contrast to IFN-sensitive FLC, IFN-resistant FLC variants were not inducible by IFN for double-stranded RNA-dependent 2-5A synthetase activity.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6301152     DOI： 10.1016/0042-6822(83)90224-6

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  10 in total

1.  Posttranscriptional regulation of beta interferon expression in erythroid Friend cells treated with gamma interferon.

Authors:  G Marziali; G Fiorucci; E M Coccia; Z Percario; J Raber; A Battistini; G B Rossi; E Affabris; G Romeo
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Expression of interferon-alpha/beta receptor protein in liver of patients with hepatitis C virus-related chronic liver disease.

Authors:  Xiang-Wei Meng; Bao-Rong Chi; Li-Gang Chen; Ling-Ling Zhang; Yan Zhuang; Hai-Yan Huang; Xun Sun
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 3.  Interferon receptors.

Authors:  A A Branca
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

4.  Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy.

Authors:  R Fukuda; N Ishimura; S Ishihara; A Tokuda; S Satoh; S Sakai; S Akagi; M Watanabe; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

5.  Influence of the site of tumor growth on the capacity of a low tumorigenic line of Friend erythroleukemia cells to differentiate.

Authors:  I Gresser; J Moss; D Woodrow; C Le Bousse; C Maury; E Proietti; F Belardelli
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

6.  Protein binding to the interferon response enhancer correlates with interferon induction of 2'-5'-oligoadenylate synthetase in normal and interferon-resistant Friend cells.

Authors:  E M Coccia; D Vaiman; J Raber; G Marziali; G Fiorucci; R Orsatti; B Cohen; N Nissim; G Romeo; E Affabris
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

Review 7.  Interferon treatment of human malignancies--a short review.

Authors:  S Einhorn; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

8.  Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.

Authors:  L Gabriele; T Kaido; D Woodrow; J Moss; M Ferrantini; E Proletti; L Santodonato; C Rozera; C Maury; F Belardelli
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

9.  Interferon-alpha resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells.

Authors:  A Brinckmann; S Axer; D Jakschies; I Dallmann; J Grosse; T Patzelt; T Bernier; A Emmendoerffer; J Atzpodien
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

10.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.

Authors:  I Gresser; F Belardelli; C Maury; M T Maunoury; M G Tovey
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.